Connext is clinical stage biotech company located in South Korea. We are developing CNT201, recombinant collagenase for Dupuytren's contracture (orthopedic) and Peyronie's disease (urology) and CNT101, most optimized TLR5 agonist-based immune modulator for immune disorder such as acute GVHD. IND for Phase 1/2 Dupuytren's contracture study was cleared by the US FDA in June 2023 and IND for acute GVHD was approved by MFDS in Korea in January 2023.